Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
Rhea-AI Summary
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, reported new multi-omics data on ART26.12, its selective FABP5 inhibitor, at the ICRS 2026 symposium in Dijon, France.
According to Artelo Biosciences, analyses across multiple disease models showed consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways, suggesting a potential mechanistic link for FABP5 inhibition’s broad therapeutic activity and supporting ongoing Phase 1 development.
Positive
- None.
Negative
- None.
News Market Reaction – ARTL
In the Jun 30 session, ARTL gained 1.82%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 29 | Clinical data update | Positive | -1.8% | Phase 1 ART26.12 data and biomarker analyses presented at ICRS 2026. |
| Jun 10 | Clinical trial data | Positive | -2.3% | Favorable ART26.12 human metabolite profile from single ascending dose study. |
| May 14 | Earnings and update | Positive | -21.4% | Q1 2026 results and pipeline milestones including ART26.12 and ART27.13. |
| Apr 28 | AI collaboration | Positive | -5.3% | Strategic AI collaboration with ScienceMachine to accelerate FABP5 program. |
| Apr 20 | Peer-reviewed publication | Positive | +1.9% | Publication supporting ART26.12 as a novel non-opioid pain treatment. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical, collaboration, and earnings updates have more often been followed by negative price reactions than by gains.
Key Terms
multi-omics technical
fabp5 medical
linoleic acid medical
mtorc1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12
SOLANA BEACH, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced results utilizing multi-omics analyses that identified a potential mechanistic links across disease models with ART26.12, the Company’s lead selective Fatty Acid Binding Protein 5 (FABP5) inhibitor that was presented at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium being held in Dijon, France.
Artelo researchers evaluated datasets generated across multiple disease models, tissues, and experimental systems to identify common biological pathways associated with treatment with ART26.12, Artelo's FABP5 inhibitor currently in Phase 1 testing. Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, announced the results in a presentation titled: Integrative Multi-Omics Across Diverse Indications Identifies Linoleic Acid as a Central Link in FABP5 Inhibition.
The analyses revealed consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways across indications, suggesting a potential mechanistic link underlying the broad therapeutic activity observed with FABP5 inhibition. This finding is consistent with a recent high-impact research paper published in Science by an independent group from Cornell University which demonstrated the linoleic acid-FABP5 axis was a key driver of cancer growth activity in a model of triple negative breast cancer1.
“When we examined datasets across diverse disease models, we identified recurring effects on linoleic acid metabolism and associated signaling pathways,” said Osborn. “These findings strengthen our understanding of FABP5 biology and provide additional support for the broad therapeutic potential of this target.”
“The results of this multi-omics analysis has not only amplified our understanding of the lipid signaling mechanism of our FABP5 inhibitor drug candidates, but has contributed to a greater appreciation of the science for our prospective pharmaceutical partners,” added Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Our scientific strategy integrates advanced analytics and translational biology to build a portfolio of differentiated therapeutics. The research with ART26.12 presented at ICRS highlights a growing body of evidence for lipid signaling modification and reinforces our commitment to advancing novel solutions for patients with significant unmet medical needs.”
Reference 1 Koundouros N, Nagiec MJ, Bullen N, Noch EK, Burgos-Barragan G, Li Z, He L, Cho S, Parang B, Leone D, Andreopoulou E, Blenis J. Direct sensing of dietary ω-6 linoleic acid through FABP5-mTORC1 signaling. Science. 2025 Mar 14;387(6739) https://www.science.org/doi/10.1126/science.adm9805
About ART26.12
ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is under development as a novel, peripherally acting, non-opioid, non-steroidal analgesic, initially for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Human studies with ART26.12 have demonstrated a favorable safety profile with no serious adverse events, as well as predictable, linear pharmacokinetics and dosing flexibility in both fed and fasted states. Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. In addition to ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
